Printer Friendly

CEPHALON, INC. RECEIVES SBIR GRANT FROM THE NIH TO RESEARCH NOVEL THERAPEUTICS FOR BRAIN AND SPINAL CORD NERVE DAMAGE AND DEGENERATION

CEPHALON, INC. RECEIVES SBIR GRANT FROM THE NIH TO RESEARCH NOVEL THERAPEUTICS FOR BRAIN AND SPINAL CORD NERVE DAMAGE AND DEGENERATION
 WEST CHESTER, Pa., June 24 /PRNewswire/ -- Cephalon, Inc. (NASDAQ: CEPH) today announced that it has received a Phase II Small Business Innovation Research (SBIR) Grant of $0.4 M from the National Institute of Mental Health of the National Institutes of Health (NIH) to develop proprietary research technologies capable of identifying compounds that promote nerve cell survival in nerve degeneration diseases such as Alzheimer's disease. This grant continues funding of the research initiated by Cephalon scientists two years ago under Phase I SBIR awards. The research is focused on the development of non- radioactive hybridization assays to accurately and rapidly identify molecules that alter the expression of key genes in the brain and spinal cord. These genes code for the production of naturally occurring neurotrophic factors that are responsible for neuronal survival.
 Additionally, Cephalon announced today the promotion of Michael E. Lewis, Ph.D. to senior director of Scientific Affairs. A co-founder of Cephalon, Dr. Lewis, age 40, served as the company's director of Pharmacology since 1987, managing drug discovery efforts. Prior to joining Cephalon, Lewis was employed at E.I. DuPont de Nemours & Co., where he spearheaded research on the regulation of gene expression in the brain. He has 20 years of experience in neuroscience research, including neurophysiology, behavioral pharmacology, neuropharmacology, neurochemistry and neuromolecular biology.
 "Since the company's founding in 1987, Michael has made numerous contributions to the progress of Cephalon's research and development programs," said Frank Baldino, Jr., Ph.D., president and chief executive officer of Cephalon, Inc. "In his new role as senior director of Scientific Affairs, Michael will focus on expanding our network of collaborative research arrangements with universities and other academic institutions and uncovering new technologies to further our discovery efforts."
 Cephalon, Inc., founded in 1987, is a neuroscience company focusing on the development of products to treat neurodegenerative diseases. Through a broad-based approach encompassing neurobiology, medicinal chemistry and recombinant DNA technology, Cephalon's researchers are developing novel molecules that can be administered via conventional means.
 -0- 6/24/92
 /CONTACT: Nicole Vitullo of Cephalon, Inc., 215-344-0200/
 (CEPH) CO: Cephalon, Inc. ST: Pennsylvania IN: MTC SU:


AH-LR -- NY003 -- 3144 06/24/92 08:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 24, 1992
Words:380
Previous Article:LENNAR'S SECOND QUARTER EARNINGS UP 52 PERCENT -- A NEW RECORD
Next Article:CHICK-FIL-A RE-OPENING ITS HISTORICAL FOREST PARK DWARF HOUSE RESTAURANT
Topics:


Related Articles
CAMBRIDGE NEUROSCIENCE GAINS ADDITIONAL NIH GRANT FOR STUDY OF COMPOUNDS TO PREVENT NEUROLOGICAL DAMAGE
CEPHALON, INC. PRESENTS PROMISING DATA ON SMALL MOLECULE NEUROTROPHIC FACTORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
CAMBRIDGE NEUROSCIENCE AWARDED PHASE II SBIR GRANT FOR SIXTH TIME; GRANT AWARDED TO FURTHER RESEARCH IN ION-CHANNEL BLOCKERS
CEPHALON PRESENTS SIGNIFICANT DISCOVERY IN ALZHEIMER'S DISEASE PROGRAM
NeuralSTEM Biopharmaceuticals Announces Issuance of U.S. Patent Covering Company's CNS Stem Cell Technology
Guilford Announces Receipt of Broad New Patents In FKBP-Neuroimmunophilin Ligand Program, Compounds That Promote Nerve Growth
BLSI INITIATES CNS NERVE REGENERATION PROGRAM FOR STROKE.
Cambridge NeuroScience Awarded a Phase II SBIR Grant for Discovery of Drugs to Treat Peripheral Nerve Dysfunction.
Velcura Therapeutics(TM), Inc. Gets Government Grant From The National Institute on Aging.
Research Grants Totaling $5.7 Million Awarded for Evaluation of Guilford Pharmaceuticals' Technologies.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters